FENC - フェネック・ファ―マシュ―ティカルズ (Fennec Pharmaceuticals Inc.) フェネック・ファ―マシュ―ティカルズ

 FENCのチャート


 FENCの企業情報

symbol FENC
会社名 Fennec Pharmaceuticals Inc (フェネック・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フェネック・ファーマシューティカルス(Fennec Pharmaceuticals Inc.)( 旧名:Adherex Technologies Inc.)はガンの治療法に焦点を当てる生物薬剤会社である。同社のリード製品は、臨床開発段階にある、チオ硫酸ナトリウム(STS)とエニルウラシルを含む。STSは、子供のシスプラチン難聴或いは耳毒性の予防のための第Ⅲ相臨床試験にある化学還元剤とする水溶性チオール化合物である。エニルウラシルは、ジヒドロピリミジン・デヒドロゲナーゼ(DPD)の不可逆阻害剤であり、主に体内で5-FUの急速な分解に関与する酵素である。   フェネック・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、主にがん治療用の医薬品の開発に従事する。チオ硫酸ナトリウムは抗がん剤のシスプラチン誘発性難聴の予防に使用、エニルウラシルは経口薬で転移性乳がんの治療に使用される。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。   Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.
本社所在地 P.O. Box 13628 68 T.W. Alexander Drive Research Triangle Park NC 27709 USA
代表者氏名 Khalid Islam ハリドイスラム
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-636-4530
設立年月日 36039
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 3人
url www.adherex.com
nasdaq_url https://www.nasdaq.com/symbol/fenc
adr_tso
EBITDA EBITDA(百万ドル) -9.15700
終値(lastsale) 7.89
時価総額(marketcap) 148284391.74
時価総額 時価総額(百万ドル) 147.15680
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 121.51680
当期純利益 当期純利益(百万ドル) -8.79700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fennec Pharmaceuticals Inc revenues was not reported. Net loss increased 73% to $4.2M. Higher net loss reflects General and administrative increase of 75% to $3M (expense) Research and development increase from $558K to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.22.

 FENCのテクニカル分析


 FENCのニュース

   Fennec Pharmaceuticals Inc Shares Close the Day 15.7% Higher - Daily Wrap  2021/04/06 22:30:00 Kwhen Finance
Fennec Pharmaceuticals Inc shares closed today 15.7% higher than it did at the end of yesterday. The stock is currently down 7.0% year-to-date, up 4.4% over the past 12 months, and up 670.0% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $6.97 and as low as $5.93 this week.Shares closed 4e+1% below its 52-week high and 4e+1% above its 52-week low.Trading volume this week was 45.5% lower than the 10-day average and 17.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -48.9% The company's stock price performance over the past 12 months beats the peer average by -147.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients  2021/05/28 12:34:31 Benzinga
Fennec Pharmaceuticals Inc (NASDAQ: FENC ) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to the ear) induced by cisplatin chemotherapy … Full story available on Benzinga.com
   Core Capital Goods Orders Post A Strong Gain In April  2021/05/28 10:00:00 Seeking Alpha
   Investors place bold bets in UK deal tussle  2021/05/28 09:45:19 Reuters
Investors in British companies are taking a stand against cheap takeovers. Shares in UK-listed groups like Spire Healthcare (SPI.L) and Vectura (VEC.L) are trading above the price of recently agreed offers. Big shareholders including Allianz Global Investors complain that some deals are too cheap, while merger arbitrageurs are betting on higher bids. But buyers have good reasons to hold firm.
   Fennec Pharmaceuticals How Have the Numbers Shaped Up for Stock market Insights & financial analysis  2021/03/11 14:12:00 Stock Market Daily
Fennec Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Fennec Pharmaceuticals Will stock surge before Earnings results? Stock market Insights & financial analysis  2021/03/05 02:19:00 Stock Market Daily
Fennec Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Fennec Pharmaceuticals (NASDAQ:FENC) Downgraded by Zacks Investment Research to Strong Sell  2020/11/20 12:46:58 Transcript Daily
Zacks Investment Research downgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a strong sell rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in […]
   Fennec Pharmaceuticals EPS misses by $0.05 (NASDAQ:FENC)  2020/11/16 12:15:09 Seeking Alpha
Fennec Pharmaceuticals (NASDAQ:FENC): Q3 GAAP EPS of -$0.24 misses by $0.05. Cash and cash equivalents were $33.2 million as of September 30, 2020. Press R
   EFFECT - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer) - Stocks News Feed  2020/11/12 05:15:19 Stocks News Feed
Accepted 2020-11-12 00:15:19 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-10 Registration Form S-3 Document Format Files Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC… Read More »EFFECT – FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フェネック・ファ―マシュ―ティカルズ FENC Fennec Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)